Vitamin D and beta‑amyloid effects on overactive parathyroid glands

Vitamin D and beta-amyloid signaling in hyperparathyroidism

NIH-funded research University of California, San Francisco · NIH-11514221

Researchers are exploring whether low vitamin D and beta‑amyloid signaling make parathyroid glands overactive in older adults.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of California, San Francisco NIH-funded
Lab location1 site (San Francisco, United States)
Project IDNIH-11514221 on NIH RePORTER

What this research studies

This project looks at how low vitamin D and related signaling pathways contribute to hyperparathyroidism, a condition where the parathyroid glands oversecrete parathyroid hormone (PTH). The team will examine molecular signals in parathyroid tissue and lab models, focusing on the vitamin D receptor, the calcium‑sensing receptor, GABAB1 receptor interactions, ADAM10, and beta‑amyloid pathways. They plan to combine experiments in the lab with analysis of human parathyroid samples to identify the steps that drive excess PTH production. The findings aim to point to biological targets that could one day lead to treatments to protect bone and muscle in older adults.

Who could benefit from this research

Good fit: Ideal candidates for related participation would be older adults with primary hyperparathyroidism or low vitamin D who can provide tissue samples or join observational studies.

Not a fit: People without parathyroid disease or those needing immediate clinical treatment are unlikely to receive direct benefit from this basic-research focused project.

Why it matters

Potential benefit: If successful, this work could reveal new targets to reduce excess parathyroid hormone and help prevent bone loss, muscle weakness, and fractures.

How similar studies have performed: Previous studies link vitamin D and the calcium‑sensing receptor to parathyroid control and the group's prior findings on GABAB1 receptor interactions are promising, but connecting beta‑amyloid signaling to hyperparathyroidism is a newer idea that needs more proof.

Where this research is happening

San Francisco, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.